146 related articles for article (PubMed ID: 26499778)
1. Simple laboratory score improves the preoperative diagnosis of adnexal mass.
Watrowski R; Zeillinger R
Tumour Biol; 2016 Apr; 37(4):4343-9. PubMed ID: 26499778
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.
Watrowski R; Heinze G; Jäger C; Forster J; Zeillinger R
Tumour Biol; 2016 Sep; 37(9):12079-12087. PubMed ID: 27207344
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
4. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
5. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
[TBL] [Abstract][Full Text] [Related]
6. Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
Reiser E; Aust S; Seebacher V; Reinthaller A; Helmy-Bader S; Schwameis R; Grimm C; Polterauer S
Gynecol Oncol; 2017 Dec; 147(3):690-694. PubMed ID: 28935270
[TBL] [Abstract][Full Text] [Related]
7. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
8. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
9. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
[TBL] [Abstract][Full Text] [Related]
10. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
Zhang F; Zhang ZL
Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
[TBL] [Abstract][Full Text] [Related]
11. Sonographic discrimination between benign and malignant adnexal masses in premenopause.
Radosa MP; Vorwergk J; Fitzgerald J; Kaehler C; Schneider U; Camara O; Runnebaum IB; Schleußner E
Ultraschall Med; 2014 Aug; 35(4):339-44. PubMed ID: 23775448
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
13. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
14. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
15. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
16. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
17. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.
Gizzo S; Berretta R; Di Gangi S; Guido M; Zanni GC; Franceschetti I; Quaranta M; Plebani M; Nardelli GB; Patrelli TS
Biomed Res Int; 2014; 2014():803598. PubMed ID: 25431767
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment.
Migda M; Bartosz M; Migda MS; Kierszk M; Katarzyna G; Maleńczyk M
J Ovarian Res; 2018 Nov; 11(1):92. PubMed ID: 30390688
[TBL] [Abstract][Full Text] [Related]
19. [Prospective study of the correlation of ultrasonography and CA125 in the management of ovarian cysts: a study of 77 cases].
Mathlouthi N; Ben Ayed B; Dhouib M; Chaabene K; Trabelsi K; Amouri H; Guermazi M
Tunis Med; 2011; 89(8-9):686-92. PubMed ID: 21948683
[TBL] [Abstract][Full Text] [Related]
20. The risk of malignancy index in discrimination of adnexal masses.
Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
